Search company, investor...

Incanthera

incanthera.com

Stage

Series A - II | Alive

Total Raised

$4.66M

Last Raised

$1.98M | 8 yrs ago

About Incanthera

Incanthera is an oncology company with a unique pipeline of technologies that target tumors. The lead cancer therapeutic opportunity is a new chemical entity called ICT2588, which has been designed to attack all forms of solid tumors while leaving healthy tissue unharmed.

Headquarters Location

Suite 315, Liverpool Science Park IC2 146 Brownlow Hill

Liverpool, England, L3 5RF,

United Kingdom

0151 331 5100

Missing: Incanthera's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Incanthera's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Incanthera

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Incanthera is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Incanthera Patents

Incanthera has filed 10 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Experimental cancer drugs
  • Monoclonal antibodies
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/1/2018

2/9/2021

Prodrugs, Experimental cancer drugs, Monoclonal antibodies, Transcription factors, Clusters of differentiation

Grant

Application Date

3/1/2018

Grant Date

2/9/2021

Title

Related Topics

Prodrugs, Experimental cancer drugs, Monoclonal antibodies, Transcription factors, Clusters of differentiation

Status

Grant

Incanthera Frequently Asked Questions (FAQ)

  • Where is Incanthera's headquarters?

    Incanthera's headquarters is located at Suite 315, Liverpool Science Park, Liverpool.

  • What is Incanthera's latest funding round?

    Incanthera's latest funding round is Series A - II.

  • How much did Incanthera raise?

    Incanthera raised a total of $4.66M.

  • Who are the investors of Incanthera?

    Investors of Incanthera include North West Fund for Biomedical, Advent International and University of Bradford.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.